The evolution of therapeutic modalities drives the adoption of single-use technologies.
AstraZeneca Restructures Vaccines R&D and Operations
July 24th 2012MedImmune, the global biologics arm of AstraZeneca, announced that it is restructuring its infectious disease and vaccines R&D and operations. This will result in the closure of MedImmune's sites in Mountain View and Santa Clara, California.